Photo: NIAID / Flickr
Scientists from Cardiff University in the UK have discovered a new type of receptors of immune cells that will help to develop an effective method of treatment of malignant tumors. This publication reports Science Alert.
Researchers have used the CRISPR-Cas9 system to detect MR1 — a new type of T-cell receptor (TCR) in the immune T-cells. This receptor functions similarly to HLA — leukocyte antigen human. It is able to recognize cancer cells, but in contrast to HLA is not much different in human populations and is more suitable as a T-cell therapy.
In the experiment using cultures of human cells of T-lymphocytes with MR1 effectively dealt with cancer cells lung, skin, colon, breast, prostate, bone, and ovaries. The results of the tests with mice that were injected with lymphocytes of MR1 showed that the new therapy leads to remission of the cancer and allows rodents to live longer than animals in the control group.
Scientists hope that clinical trials involving humans will begin later this year. It is not known how many types of cancer sensitive to a new immunotherapy.
Video, photo All from Russia.